Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner

OATP1B1 and OATP1B3 mediate hepatic uptake of many drugs (e.g., statins) and can mediate transporter-mediated drug-drug-interactions (DDIs). Bortezomib is the first-in-class proteasome inhibitor drug approved by the U. S. Food and Drug Administration for the treatment of multiple myeloma. The potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Alam, Khondoker, Farasyn, Taleah, Crowe, Alexandra, Ding, Kai, Yue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673231/
https://www.ncbi.nlm.nih.gov/pubmed/29107984
http://dx.doi.org/10.1371/journal.pone.0186924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673231/
https://www.ncbi.nlm.nih.gov/pubmed/29107984
http://dx.doi.org/10.1371/journal.pone.0186924

Ejemplares similares